XOMA ROYALTY CORP (XOMA) competitors & alternatives
Health Care · NASDAQ
XOMA ROYALTY CORP (XOMA)'s top competitors and alternatives — its most similar public companies — include Royalty Pharma (RPRX), SILVERCREST ASSET MANAGEMENT GROUP (SAMG), PTC THERAPEUTICS INC (PTCT), VOR BIOPHARMA INC (VOR), ROCKET PHARMACEUTICALS INC (RCKT), PACIRA BIOSCIENCES INC (PCRX), BENITEC BIOPHARMA INC (BNTC), VOYAGER THERAPEUTICS INC (VYGR), MaxCyte, Inc. (MXCT), Fractyl Health, Inc. (GUTS), Sarepta Therapeutics (SRPT) and Organon & Co. (OGN). These are XOMA ROYALTY CORP's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top XOMA competitors & alternatives
-
Royalty PharmaRPRXHealth Care
Royalty Pharma is the leading financier of pharmaceutical innovation, providing capital in exchange for long-term royalty streams on top-tier commercial drug…
$58.72 (as of 2026-07-22) · market cap $33.8B
-
SILVERCREST ASSET MANAGEMENT GROUPSAMGFinancials
Silvercrest is a boutique wealth and asset management firm providing customized investment strategies and family office services to high-net-worth clients.
$10.09 (as of 2026-07-22) · market cap $116M
-
PTC THERAPEUTICS INCPTCTHealth Care
PTC Therapeutics develops precision medicines and gene therapies targeting rare genetic disorders and serious diseases, generating revenue from approved…
$78.40 (as of 2026-07-22) · market cap $6.5B
-
VOR BIOPHARMA INCVORHealth Care
Vor Biopharma is a clinical-stage biopharmaceutical company developing advanced cell therapy and gene therapy solutions for blood disorders and cancers.
$19.51 (as of 2026-07-22) · market cap $1.1B
-
ROCKET PHARMACEUTICALS INCRCKTHealth Care
Rocket Pharmaceuticals is a clinical-stage biotechnology company developing transformative gene therapies for rare, high-unmet-need genetic disorders.
$3.30 (as of 2026-07-22) · market cap $368M
-
PACIRA BIOSCIENCES INCPCRXHealth Care
Pacira BioSciences is a non-opioid pain management company commercializing injectable, device, and gene therapy treatments for postsurgical and osteoarthritis…
$25.59 (as of 2026-07-22) · market cap $1.0B
-
BENITEC BIOPHARMA INCBNTCHealth Care
Benitec is a clinical-stage gene therapy company developing DNA-directed RNA interference (ddRNAi) treatments delivered via adeno-associated viral vectors to…
$11.44 (as of 2026-07-22) · market cap $396M
-
VOYAGER THERAPEUTICS INCVYGRHealth Care
A gene therapy company developing AAV-based therapeutics and non-viral treatments for neurological diseases, relying heavily on partnership revenue while…
$3.10 (as of 2026-07-22) · market cap $187M
-
MaxCyte, Inc.MXCTHealth Care
MaxCyte enables cell therapy development through proprietary electroporation technology that delivers molecules into cells for engineering next-generation…
$1.14 (as of 2026-07-22) · market cap $125M
-
Fractyl Health, Inc.GUTSHealth Care
Fractyl Health is a clinical-stage medical device and gene therapy company developing the Revita mucosa resurfacing procedure and Rejuva gene therapy platform…
$0.76 (as of 2026-07-22) · market cap $123M
-
Sarepta TherapeuticsSRPTHealth Care
A biopharmaceutical leader in genetic medicine, specializing in innovative RNA-targeted therapies and gene treatments for Duchenne muscular dystrophy and rare…
$15.82 (as of 2026-07-22) · market cap $1.7B
-
Organon & Co.OGNHealth Care
A diversified pharmaceutical company spun from Merck focusing on established branded medicines and medical devices for women's health, infectious disease, and…
$13.52 (as of 2026-07-22) · market cap $3.6B
Not quite? Describe exactly what you want →
Peers are XOMA ROYALTY CORP's closest public companies by shared sub-industry, sector and business themes. See the full profile: XOMA ROYALTY CORP (XOMA).
Last updated 2026-07-21.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.